Supernus Pharmaceuticals Inc SUPN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SUPN is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $33.78
- Day Range
- $33.46–34.08
- 52-Week Range
- $22.07–39.09
- Bid/Ask
- $33.60 / $33.72
- Market Cap
- $1.84 Bil
- Volume/Avg
- 116,156 / 400,840
Key Statistics
- Price/Earnings (Normalized)
- 125.48
- Price/Sales
- 3.08
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 652
- Website
- https://www.supernus.com
Comparables
Valuation
Metric
|
SUPN
|
ITCI
|
NEU
|
---|---|---|---|
Price/Earnings (Normalized) | 125.48 | — | 17.17 |
Price/Book Value | 2.00 | 11.36 | 13.41 |
Price/Sales | 3.08 | 14.46 | 11.97 |
Price/Cash Flow | 15.58 | — | 15.01 |
Price/Earnings
SUPN
ITCI
NEU
Financial Strength
Metric
|
SUPN
|
ITCI
|
NEU
|
---|---|---|---|
Quick Ratio | 1.38 | 4.95 | 5.68 |
Current Ratio | 1.70 | 5.41 | 5.78 |
Interest Coverage | −2.18 | — | — |
Quick Ratio
SUPN
ITCI
NEU
Profitability
Metric
|
SUPN
|
ITCI
|
NEU
|
---|---|---|---|
Return on Assets (Normalized) | 2.53% | −13.47% | 122.78% |
Return on Equity (Normalized) | 4.09% | −15.88% | 141.09% |
Return on Invested Capital (Normalized) | 2.73% | −17.96% | 137.22% |
Return on Assets
SUPN
ITCI
NEU
Drug Manufacturers - Specialty & Generic Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Phnqdytjg | Vcm | $77.2 Bil | |
MKKGY
| Merck KGaA ADR | Mcxgggfx | Bdcws | $75.4 Bil | |
HLN
| Haleon PLC ADR | Yywfqbvrz | Xzx | $38.1 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Dnnlwdmzt | Wtzj | $16.0 Bil | |
VTRS
| Viatris Inc | Btqtpjk | Gnsj | $14.0 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Qngjxlrb | Jsqg | $12.1 Bil | |
CTLT
| Catalent Inc | Cmmnmws | Zspvfgv | $10.2 Bil | |
PRGO
| Perrigo Co PLC | Crkzmpgr | Wsv | $4.3 Bil | |
CURLF
| Curaleaf Holdings Inc | Dshqlpqb | Xzkj | $4.0 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Cswwfcc | Zhnft | $3.6 Bil |